Free tool
FAERS Monitor: Gleolan
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208630 or its brand name (Gleolan, Aminolevulinic Acid Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
161
Serious
83
52% of reports
Hospitalization
21
Death reported
7
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective46
- hypotension31
- vomiting11
- inappropriate schedule of product administration9
- cardiac arrest7
- nausea7
- photosensitivity reaction7
- blood pressure decreased6
- seizure6
- atrial fibrillation5
- hepatic function abnormal5
- loss of consciousness5
- off label use5
- shock5
- acute respiratory distress syndrome4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2018 | 2 |
| 2019 | 27 |
| 2020 | 19 |
| 2021 | 6 |
| 2022 | 18 |
| 2023 | 24 |
| 2024 | 27 |
| 2025 | 19 |
| 2026 | 14 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,998 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| photosensitivity reactionSignal | 7 | 55.4 | 26.8 | 322 |
| acute respiratory distress syndromeSignal | 4 | 29.6 | 11.2 | 84 |
| shockSignal | 5 | 28.4 | 12.0 | 106 |
| hypotensionSignal | 31 | 20.2 | 14.7 | 552 |
| hepatic function abnormalSignal | 5 | 17.5 | 7.4 | 62 |
| blood pressure decreasedSignal | 6 | 11.8 | 5.4 | 49 |
| cardiac arrestSignal | 7 | 11.1 | 5.4 | 55 |
| seizureSignal | 6 | 6.8 | 3.1 | 24 |
| atrial fibrillationSignal | 5 | 6.7 | 2.8 | 19 |
| inappropriate schedule of product administrationSignal | 9 | 6.5 | 3.5 | 37 |
| loss of consciousnessSignal | 5 | 5.1 | 2.2 | 13 |
| drug ineffectiveSignal | 46 | 4.6 | 3.6 | 133 |
| vomitingSignal | 11 | 3.1 | 1.7 | 14 |
| nausea | 7 | 1.2 | 0.6 | 0 |
| off label use | 5 | 0.7 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.